Disclosed herein is a pharmaceutical combination for use in the treatment of squamous cell carcinoma, comprising a CDK inhibitor selected from benzopyran (chromene) compounds of formula (I), wherein the substituents are as defined in the specification and one or more antineoplastic agents selected from sorafenib, lapatinib, erlotinib, cisplatin, 5-fluorouracil, docetaxel or cetuximab. The said pharmaceutical combination exhibits synergy when used in the treatment of squamous cell carcinoma of head and neck (SCCHN). Also disclosed is the use of the pharmaceutical composition comprising the said combination for the manufacture of a medicament for the treatment of squamous cell carcinoma of head and neck (SCCHN).
